1. BESPOKE. SPECIFIC. EFFICIENT
Synpromics Ltd
Re-writing the source code for life to better harness the power of the genome for commercial applications
Dr David Venables, CEO
BESPOKE. SPECIFIC. EFFICIENT

2. Investment Overview
Cutting edge, IP generating, company in the emerging field of Synthetic Biology.
Platform technology and IP has broad application across biotechnology; enabling more optimal commercial exploitation of The Genome Project.
Multiple revenue generating opportunities through development milestone payments and attractive royalties.
Low risk investment strategy, with short term revenue and long term revenue growth from rich royalty stream.
Partnering agreements already in place – validated approach.
Experienced Board and Management Team.

3. Synpromics Board
Chairman: Dr John Brown, CBE, FRSE is the Chairman of the Cell Therapy Catapult, Mode Diagnostics Ltd and CXR Biosciences Ltd and a Non-Executive Director of Vectura Group plc. Previously, he was the Chairman of BTG plc, Axis-Shield plc, and, CEO of Acambis plc, and was a Director of Cambridge Antibody Technology plc until its acquisition by AstraZeneca. John also chairs the Roslin Foundation and co-chairs the Life Sciences Industry Advisory Board for the Scottish Government.
CEO: David Venables, BSc, PhD has served as CEO of Anatara Therapeutics (a life sciences company he managed through private fund raising and IPO in Australia), CEO of Ark Therapeutics (until the sale of the company), and Managing Director of BioMelior Services Ltd, providing management and consultancy services to the biopharmaceutical industry and investment funds in the areas of bioprocess CMC, CMO/CRO services and business & product development strategy within the vaccine, gene therapy and cell therapy sectors. Previously at Intercell, he was responsible for building Intercell’s manufacturing capabilities in Europe and the USA. As Site Head for vaccine manufacturing operations in the UK he was responsible for the European and US licensure, pre-approval inspection and commercial supply of Ixiaro®, a Japanese Encephalitis vaccine, followed as Chief Operating Officer of Intercell USA Inc. based in the USA.
Founder & CSO: Michael Roberts, BSc, PhD is the founder of Synpromics and developed the science behind the company's technology. He has extensive experience in the biotech industry and academia developing novel tools for genetic engineering. Michael graduated from the University of Glasgow with first class honours and completed his PhD at Cambridge University. Following academic roles at Royal Holloway University of London and the National Hellenic Research Foundation (as a prestigious Marie Curie Fellow), he joined Regulon Inc., as head of Research & Development and Board Member, where he remained until 2009 prior to founding Synpromics.
NXD: David Lawrence is a highly experienced, dynamic business professional with a wide experience in leadership, strategy, business development, commercial/ operational management and trouble shooting. His experience over 25 years spans a variety of sectors in Lifesciences including pharmaceuticals, vaccines and biotech/medtech. David also has extensive international experience of mergers and acquisitions, fund raising and investor relations. Previous roles have included: Vice-President of Finance at GSK, Vice-President of Finance, Business Development and Strategy at Chiron Vaccines, CFO at Acambis PLC, (Board member of dual FTSE and NASDAQ listed company), CEO at Tayside Flow Technologies, a privately backed Medtech company and formerly Chairman at Acambis, a privately owned medical devices company. David is currently CEO of Sentinext Therapeutics, a vaccines company based in Malaysia.

4. Capital Structure Shareholder Number of Share % Investment to Date £
Michael L Roberts
325,000
39.3
David Lawrence
149,000
18.0
David Venables
100,000
12.1
Andrei Lyne
75,000
9.1
Others
178,050
21.5
Investment to Date
Seed Investment
270,000
Convertible Instruments
500,000
Grants
725,000
TOTAL
1,495,000

5. Synpromics: Global leader in synthetic biology;
Create synthetic promoter technology and IP to enable the controlled expression of a protein product in:
a specific place,
a specific environment
a specific time
response to a specific biological condition
Partners will adopt our IP in a wide range of biotechnology applications
The universality of the application, and specificity of control, means that every gene derived product can benefit from using Synpromics synthetic promoter IP.

6. Better Products - Better Processes
The value of Promoters
Biotechnology is based on the commercial exploitation of gene technology to create:
novel therapeutic products to treat, and in
some cases cure, disease
personalised & regenerative medicines
smarter diagnostics
The power, and value, of novel technologies is increasingly reliant on the advancing the underlying mechanisms of gene & drug delivery.
Synthetic promoters will be a key enabling & differentiating tool in the delivery of next generation therapeutic and regenerative medicines.
Better Products - Better Processes

7. Better than existing promoters
Feature
Viral
Natural
Synthetic
High production levels
YES NO
Predictable production for all proteins
Constitutive (non-stop) production
Active in multiple cell types
Temporal regulation of production
Cell type - specific control
Multiple genes stably delivered in one product
Inducible upon biological/chemical stimuli
Temperature sensitive

8. Cell & Gene Therapy and DNA Vaccine Market Opportunity
The Application
Delivering a therapeutic gene to the patient
Higher-producing vectors and cell lines, reducing manufacturing scale / cost of goods and overcoming the current limitations of scale-up.
Targeting vector transgene expression to improve product safety and increase efficacy, overcoming current off-target gene expression.
Improved targeting of autologous and allogeneic cell therapies in regenerative medicine and cancer treatment.
The Market
Gene and Cell Therapy is a rapidly emerging market with high unmet need and low barrier of entry to Synpromics IP
Current gene therapy market opportunity for Hemophilia A est. $650 million
$13 million annual revenue opportunity for Synpromics in this one indication
Current Status
DNA vaccine collaboration agreement in place with commercial partner.
AAV collaboration agreement in place with commercial partner

9. Bio-Processing Market Opportunity
The Application
Synthetic promoters driving increased protein yield, reducing process scale and reducing cost of goods.
Increasing efficiency and yield of difficult to produce therapeutics.
Improved adaptation of producer cell lines to industrial production environment.
The Market
Forecast biomedicine market value of $287 billion by 2020
A conservative 1% market penetration of Synpromics IP represents $60 million annual revenue
Forecast industrial biofuels market value of $184 billion by 2021
Current Status
3 Funded proof of concept studies in progress
Term sheet for partner program in CHO cell line development under discussion

10. Use of Funds 2015 2016 TOTAL Operational Costs £330,000 £435,000
£765,000
G&A Costs
£175,000
£250,000
£425,000
Project Costs
(A) Bioprocessing
£170,000 -
(B) Cell and Gene Therapy
£130,000
£430,000
£560,000
(C) Platform
£103,050
£273,050
Total Program Costs
£470,000
£533,050
£1,003,050
Total Program Costs net R&D Tax Credits
£329,000
£373,135
£702,135
TOTAL TO RAISE
£834,000
£1,058,135
£1,892,135

11. Staged Use of Funds The initial £850,000 investment allows:
Completion of current projects and commercialisation of resulting promoters
Initiation and completion of NGS screening approach allowing the company to develop its 3rd generation promoter technology and proprietary databases
Initiation of the lentiviral library system to improve efficiency of screening
Initiation of additional Bioprocessing project
Business development activities to increase and convert on new business leads
The second £1,150,000 investment:
Triggered upon completion of CHO, Ingenza, Touchlight & Synthace projects
Allows completion of Bioprocessing, NGS Screening and Lentiviral projects
Allows initiation of two additional projects in the cell and gene therapy sector
Allows initiation of four additional projects in the cell and gene therapy sector
Allows increase in business development activities, including key BD hire

12. Defining The Next Frontier
Synpromics promoter IP will become the technology of choice in the biotech industry because it provides:
unique and synthetic promoters;
sequence and application are patentable
custom designed promoters for maximum productivity and stability
promoters which are controllable, and non-leaky, by time, place and environment
promoters specific to target tissue or biological condition
promoters ubiquitous in their application across all cell & gene derived products.

13. Appendix
Supplementary Slides

14. Key Company Milestones
Patent Application for core technology
Proof-of-concept in colorectal cancer
POC Project with Avanticell (co-funded Innovate UK)
Commercial project initiated with Dow Agrosciences (DAS; co-funded by SE SMART)
SynBio POC for creating CHO cell promoters (co-funded by Innovate UK)
Scientific team increased to 3 x PhDs
Commercial project with Ingenza for yeast promoters (co-funded Innovate UK);
Commercial project with Touchlight Genetics (co-funded Innovate UK);
POC Project with Synthace (co-funded Innovate UK)
Two patent applications submitted relating to screening in plants and mammalian cells
Three new patent applications being prepared relating to super-expressing promoters, protoplast screening method and NGS screening
Advanced stage of negotiations for projects with uniQure and Lonza
Licensing out protoplast screening method to DAS resulting in the removal the DAS £250k (plus interest) charge to the company
Q1 2012: 1st seed round: £ per share post money = £1.0 million
Q3 2012: 2nd seed round: £1.666 per share post-money = £1.5 million
Q4 2014: 1st series A: £TBD per share post-money = £TBD million

15. Timing of Project Activities
£850k Investment
£1050k Investment
2015
2016
BD Activities
CHO
Bioprocess Collaboration
Ingenza
Touchlight
Synthace
Undisclosed AAV Collaboration
NGS Screening
Lentiviral Libraries
Occular
Muscle
BioProcessing New Project Q1
Brain
BioProcessing New Project Q3
Heart
Platform
Cell / Gene Therapy Project
Bioprocessing Project
Completion of CHO, Ingenza, Touchlight & Synthace projects used as trigger for 2nd tranch of funding

16. IP Strategy Patent Submitted, 2011 - National Phase
Bioinformatics proprietary selections algorithms
NGS screening methodologies and barcoded libraries
Library Construction SOP
Proprietary database of cis-element interactions
Methods to screen libraries in specific cell types
Proprietary plasmid/ viral screening vectors
Panels of synthetic promoters specific to target condition
Patent Submitted, National Phase
Patent Application in Preparation
Patent Submitted, 2014
Patent Application in Preparation

17. Example Deal Terms Example Revenue Milestone
Upfront payment to access our platform technology will allow the partner access to our libraries in order to select specific promoters for defined fields of use  £
Where appropriate milestone payments at following points:
Selection of promoter
50.000 £
Successful phase 1 / 2  £
Successful phase 3  £
Regulatory filing / commercial approval
Royalties on net income derived from product incorporating a Synpromics promoter
2.5% - 5.0%
* Synpromics reserves right to produce other promoters for the same field of use